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SUMMARY. The hepatitis C virus (HCV) epidemic was
forecasted through 2030 for 15 countries in Europe, the Mid-
dle East and Asia, and the relative impact of two scenarios
was considered: [1] increased treatment efficacy while hold-
ing the annual number of treated patients constant and [2]
increased treatment efficacy and an increased annual num-
ber of treated patients. Increasing levels of diagnosis and
treatment, in combination with improved treatment efficacy,
were critical for achieving substantial reductions in disease
burden. A 90% reduction in total HCV infections within
15 years is feasible in most countries studied, but it required
a coordinated effort to introduce harm reduction
programmes to reduce new infections, screening to identify
those already infected and treatment with high cure rate
therapies. This suggests that increased capacity for screening
and treatment will be critical in many countries. Birth cohort
screening is a helpful tool for maximizing resources. Among
European countries, the majority of patients were born
between 1940 and 1985. A wider range of birth cohorts was
seen in the Middle East and Asia (between 1925 and 1995).
Keywords: diagnosis, disease burden, elimination, epidemi-
ology, hepatitis C, hepatitis C virus, incidence, mortality,
prevalence, scenarios, strategy, treatment.
Abbreviations: DAA, direct-acting antiviral agent; G, Genotype; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IDU, injection drug
use; Peg-IFN, Pegylated interferon; RBV, ribavirin; SVR, sustained viral response.
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INTRODUCTION
Although the prevalence of hepatitis C virus (HCV) is
decreasing in many countries, there is an expected increase
in HCV-related morbidity and mortality as the prevalent
population ages and progresses to more advanced disease
stages. The previous publications in this supplement
demonstrated the expected disease burden if no changes
were made to the current treatment paradigm. However, it
is reasonable to assume that changes will occur, due to
current and future adoption of new, more efficacious thera-
pies. This study was designed to demonstrate the potential
impact that various disease control strategies, both conser-
vative and aggressive, might have on the future HCV dis-
ease burden in individual countries. The results are not
intended to stipulate the adoption of these specific strate-
gies, but rather to illustrate what outcomes might be possi-
ble should similar intervention strategies be implemented.
METHODOLOGY
The details of the model used to forecast HCV disease burden
were described previously [1–3]. The model interface
allowed for changing assumptions of the number of patients
treated, the proportion of cases eligible for treatment, the
reduction in treatment restrictions, the average sustained
viral response (SVR) by genotype, the number of newly diag-
nosed individuals and the number of new infections at five
different points in time. The year in which these changes
took effect was also an input field. A variety of new therapies
were considered, including: direct-acting antivirals (DAAs) +
pegylated interferon (Peg-IFN) + ribavirin (RBV), DAA +
RBV, interferon-free all-oral, second-generation DAA combi-
nations and third-generation combinations. All changes
took effect immediately, and the co-existence of multiple
therapies was handled by modifying the average SVR.
The future number of treated patients was capped by (i)
number diagnosed, (ii) number eligible and (iii) unre-
stricted cases. The latter related to implicit (defined by
physician’s practice) and/or explicit (defined by treatment
guidelines) restrictions. These restrictions could be modified
by changing the upper and lower end of patients’ age and
their stage of fibrosis (≥F4, ≥F3, ≥F2, ≥F1 or ≥F0). Review
of treatment guidelines and interviews with expert panels
were used to identify both. While age restrictions were
applied to all genotypes, the restrictions by the stage of
liver disease were applied to specific genotypes. Patients
with decompensated cirrhosis, irrespective of genotype,
were considered ineligible for any treatment that involved
Peg-IFN. The fibrotic stages eligible for treatment are
shown in Figs 1–15. When the number of treated patients
was greater than those diagnosed, eligible and unrestricted,
the number of newly diagnosed cases was increased or the
treatment restrictions were relaxed. The focus of the analy-
sis was to highlight how many cases have to be diagnosed
to achieve a strategy rather than to forecast the screening
capacity in a country.
According to the literature, approximately 40–60% of
HCV patients are eligible for Peg-IFN/RBV treatment [4–6].
The definition of eligibility included lack of contraindications
to the drugs (e.g. psychiatric conditions) as well as patients’
preference. For all countries, a treatment eligibility of 60%
was used for all therapies that included Peg-IFN/RBV. When
Peg-IFN could be eliminated, the eligibility was increased.
The increase in eligibility did not increase treatment in the
future. However, it did increase the pool of diagnosed and
eligible patients who could be treated. Any changes in treat-
ment were implemented using a separate input.
In this analysis, three strategies were considered – base,
increased efficacy only and increased efficacy and treat-
ment. The base strategy was defined as the case when all
assumptions (the number of acute cases, treated patients,
percent of patients eligible for treatment, treatment restric-
tions, the number of newly diagnosed and the average
SVR by genotype) remained the same as today. This was
assumed to be the most conservative, but feasible, scenario.
Even more conservative scenarios are possible (e.g., stop
treating HCV patients completely), but those were deemed
to be unlikely. The base scenario for each country was
described in detail previously [1]. In the second strategy,
the impact of increasing the SVR of therapies was consid-
ered. The number of treated patients remained the same as
in the base strategy. In a few countries, treatment restric-
tions were relaxed if there were no longer enough patients
left to treat in the future. However, all other assumptions
remained consistent with the base strategy.
The third scenario included an increase in both SVR and
treatment uptake. The assumptions for the number of trea-
ted patients in the future were often driven by a desire to
achieve a certain goal (i.e. control HCV disease burden)
and were developed in discussion with expert panels in
each country. To achieve some of these strategies, expand-
ing access to patients with early stages of fibrosis (F0–F2)
was considered. In most instances, the number of newly
diagnosed cases also had to be increased to keep up with
the depletion of the diagnosed eligible patient pool.
Scenario inputs, including SVR, fibrosis stage and medi-
cal eligibility are provided, by genotype and year, in
Figs 1–15. The numbers of treated and diagnosed patients
necessary to achieve the desired scenario outputs are also
provided.
In all instances, viremic infections represented current
HCV or chronic HCV infections. The term viremic was used
throughout this study to highlight the presence of HCV
virus. The term incidence was used for new HCV infections
and not newly diagnosed. Hepatocellular carcinoma (HCC)
referred to the total number of viremic HCV-related HCC
cases, rather than new cases. Additionally, all reductions
© 2015 John Wiley & Sons Ltd
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Fig. 1 Estonia model inputs, by year.
Fig. 2 Hungary model inputs, by year.
Fig. 3 Iceland model inputs, by year.
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Fig. 4 Indonesia model inputs, by year.
Fig. 5 Iran model inputs, by year.
Fig. 6 Japan model inputs, by year.
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Fig. 7 Latvia model inputs, by year.
Fig. 8 Lebanon model inputs, by year.
Fig. 9 Lithuania model inputs, by year.
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Fig. 10 Pakistan model inputs, by year.
Fig. 11 Romania model inputs, by year.
Fig. 12 Saudi Arabia model inputs, by year.
© 2015 John Wiley & Sons Ltd
48 F. Z. Alfaleh et al.
Fig. 13 Slovenia model inputs, by year.
Fig. 14 South Korea model inputs, by year.
Fig. 15 UAE model inputs, by year.
© 2015 John Wiley & Sons Ltd
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by disease stage were assumed to occur among the viremic
HCV population – that is, the effects of non-HCV-related
liver disease were not considered in this analysis.
Birth cohort effect
The age distribution of each country was gathered from
published data and reported previously [7]. The disease
progression model was used to age the HCV-infected pop-
ulation after taking into account mortality and SVR [1].
For this analysis, the median age in each five-year age
cohort was selected and converted to a birth year. A
range of birth years was selected that accounted for
approximately 70% (or more) of the total HCV-infected
population using the 2014 HCV population distribution
[1].
Fig. 16 Change in HCV morbidity and mortality, by scenario, 2014–2030.
© 2015 John Wiley & Sons Ltd
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RESULTS
The results of the analyses are summarized in Fig. 16. The
birth cohort effect in the HCV-infected population is shown
in Fig. 17. Each bar represents the range of birth years,
with the value on each bar showing the percentage of the
total infected population who were born between the years
shown. Country-specific scenario results are discussed
below.
Estonia
Increased efficacy only
There would be 1200 fewer viremic individuals in 2030, a
9% reduction as compared to the base case. The number
of HCC cases in 2030 was estimated at 25 cases, a 60%
decrease from the base case. Similarly, the number of liver-
related deaths would decrease by 70% from the base, with
25 in 2030. Decompensated and compensated cirrhosis
Fig. 16 continued
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would decrease by 75% and 50%, respectively, from the
base, with 50 and 1000 cases in 2030.
Increased efficacy & treatment uptake
There would be 6900 fewer viremic individuals in 2030, a
50% reduction as compared to the base case. The number
of HCC cases in 2030 was estimated at 20 cases, a 70%
decrease from the base case. Similarly, the number of liver-
related deaths would decrease by 70% from the base, with
25 in 2030. Decompensated and compensated cirrhosis
would decrease by 80% and 60%, respectively, from the
base, with 45 and 860 cases in 2030.
Hungary
Increased efficacy only
There will be 5000 fewer viremic individuals in 2030, a
10% reduction as compared to the base case. The number
of HCC cases in 2030 was estimated at 330 cases, a 20%
decrease from the base case. Similarly, the number of
Fig. 16 continued
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liver-related deaths will decrease by 20% from the base,
with 360 deaths in 2030. Decompensated and compen-
sated cirrhosis will decrease by 25% and 20% from the
base, with 470 and 5100 cases in 2030.
Increased efficacy & treatment uptake
With an aggressive treatment strategy, there will be
46 600 fewer viremic individuals in 2030, a 90%
reduction as compared to the base case. The number of
HCV-related HCC cases in 2030 was estimated at 0
cases, a 100% decrease from the base case. Similarly,
the number of HCV-related liver-related deaths will
decrease by 100% from the base, with 1 death in 2030.
HCV-related decompensated and compensated cirrhosis
will decrease by 100% from the base, with 0 and 2
cases in 2030. HCV-related liver transplants would
decrease by 90% from the base, from 21 to 2 cases in
2030.
Fig. 16 continued
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Iceland
Increased efficacy only
There would be 80 fewer viremic individuals in 2030, a
5% reduction as compared to the base case. The number
of HCC cases in 2030 was estimated at 4 cases, an 8%
decrease from the base case. The number of liver-related
deaths would decrease by 7% from the base, with 6
deaths1 in 2030. Decompensated and compensated
cirrhosis would decrease by 8% from the base, with 12
and 130 prevalent cases in 2030.
Increased efficacy & treatment uptake
With an aggressive treatment and diagnosis strategy,
there would be 1200 fewer viremic individuals in
2030, a 95% reduction as compared to the base case.
The number of HCC cases in 2030 was estimated at 1
case, an 80% decrease from the base case. Similarly,
the number of liver-related deaths would decrease by
70% from the base, with 2 deaths in 2030. Decompen-
sated and compensated cirrhosis would decrease by
75% from the base, with 4 and 30 cases, respectively,
in 2030.
Fig. 16 continued
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Indonesia
Increased efficacy only
There would be 290 fewer viremic individuals in 2030,
a < 1% reduction as compared to the base case. The
number of HCC cases in 2030 was estimated at 5300
cases, a < 1% decrease from the base case. Similarly, the
number of liver-related deaths would decrease by <1%
from the base, with 7700 in 2030. Decompensated and
compensated cirrhosis would decrease by <1% from the
base, with 19 400 and 172 000 cases in 2030.
Increased efficacy & treatment uptake
There would be 600 000 fewer viremic individuals in 2030,
a 50% reduction as compared to the base case. The number
of HCC cases in 2030 was estimated at 1800 cases, a 70%
decrease from the base case. Similarly, the number of liver-
related deaths would decrease by 60% from the base, with
Fig. 16 continued
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2900 deaths in 2030. Decompensated and compensated
cirrhosis would decrease by 60% and 70%, respectively,
from the base, with 7300 and 56 000 cases in 2030.
Iran
Increased efficacy only
There would be 26 700 fewer viremic individuals in 2030,
a 13% reduction as compared to the base case. The num-
ber of HCC cases in 2030 was estimated at 300 cases, a
7% decrease from the base case. Similarly, the number of
liver-related deaths would decrease by 7% from the base,
with 400 deaths in 2030. Decompensated and compen-
sated cirrhosis would decrease by 10% and 7% from the
base, with 590 and 10 100 cases in 2030.
Increased efficacy & treatment uptake
Utilizing an aggressive treatment and diagnosis strategy,
there would be a 90% reduction in the total number of
viremic individuals, representing 196 000 fewer viremic
Fig. 16 continued
© 2015 John Wiley & Sons Ltd
56 F. Z. Alfaleh et al.
individuals in 2030, relative to the base case. The number
of HCC cases in 2030 was estimated at 40 cases, a 90%
decrease from the base case. Similarly, the number of liver-
related deaths would decrease by 85% from the base, with
70 deaths in 2030. Decompensated and compensated cir-
rhosis would decrease by 80% and 90% from the base,
with 140 and 1300 cases in 2030.
Japan
Increased efficacy only
There would be 64 500 fewer viremic individuals in 2030,
a 25% reduction as compared to the base case. The num-
ber of prevalent HCC cases in 2030 was estimated at
53 600 cases, a 20% decrease from the base case, while
the number of incident HCC cases in 2030 was estimated
at 3300, a 45% decrease from the base case. The number
of liver-related deaths would decrease by 35% from the
base, with 9300 deaths in 2030. Decompensated and com-
pensated cirrhosis would decrease by 85% and 40% from
the base, with 2400 and 50 700 cases, respectively, in
2030.
Increased efficacy & treatment uptake
With an aggressive treatment and diagnosis strategy, there
would be 159 000 fewer viremic individuals in 2030, a
60% reduction as compared to the base case. The number
of prevalent HCC cases in 2030 was estimated at 49 300
cases, a 30% decrease from the base case, while the num-
ber of incident HCC cases in 2030 was estimated at 1500,
Fig. 16 continued
Fig. 17 Distribution of HCV-infected population by birth year cohort.
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a 75% decrease from the base case. Similarly, the number
of liver-related deaths would decrease by 40% from the
base, with 8700 deaths in 2030. Decompensated and com-
pensated cirrhosis would decrease by 95% and 80% from
the base, with 950 and 17 700 cases, respectively, in
2030.
Latvia
Increased efficacy only
There would be 4400 fewer viremic individuals in 2030, a
9% reduction as compared to the base case. The number
of HCC cases in 2030 was estimated at 110 cases, a 15%
decrease from the base case. Similarly, the number of liver-
related deaths would decrease by 15% from the base, with
160 deaths in 2030. Decompensated and compensated
cirrhosis would decrease by 15% from the base, with 380
and 3800 cases in 2030.
Increased efficacy & treatment uptake
With treatment of 1530 patients annually beginning in
2018, there would be 12 200 fewer viremic individuals
in 2030, a 25% reduction as compared to the base case.
The number of HCC cases in 2030 was estimated at 80
cases, a 40% reduction from the base case. Similarly, the
number of liver-related deaths would decrease by 40%
from the base, with 110 deaths in 2030. Decompensated
and compensated cirrhosis would decrease by 45% and
40% respectively, from the base, with 240 and 2700
cases in 2030.
Lebanon
Increased efficacy only
There would be 680 fewer viremic individuals in 2030, a
9% reduction as compared to the base case. The number
of HCC cases due to HCV in 2030 was estimated at 30
cases, a 19% decrease from the base case. Similarly, the
number of liver-related deaths would decrease by 20%
from the base, with 40 deaths in 2030. Decompensated
and compensated cirrhosis would decrease by 25% and
15%, respectively, from the base, with 80 and 900 cases
in 2030.
Increased efficacy & treatment uptake
With an aggressive increase in treated patients, there
would be 6700 fewer viremic individuals in 2030, a 90%
reduction as compared to the base case. The number of
HCC cases due to HCV in 2030 was estimated at 6 cases,
an 80% decrease from the base case. Similarly, the number
of liver-related deaths would decrease by 75% from the
base, with 11 deaths in 2030. Decompensated and
compensated cirrhosis would decrease by 75% and 80%,
respectively, from the base, with 30 and 210 cases in
2030.
Lithuania
Increased efficacy only
There would be 2700 fewer viremic individuals in 2030,
an 8% reduction as compared to the base case. The num-
ber of HCC cases in 2030 was estimated at 110 cases, an
8% decrease from the base case. Similarly, the number of
liver-related deaths would decrease by 8% from the base,
with 140 deaths in 2030. Decompensated and compen-
sated cirrhosis would decrease by 9% and 8%, respectively,
from the base, with 310 and 3600 cases in 2030.
Increased efficacy & treatment uptake
With an aggressive increase in treated patients, there
would be 31 500 fewer viremic individuals in 2030, a
90% reduction as compared to the base case. The number
of HCC cases in 2030 was estimated at 15 cases, an 85%
decrease from the base case. Similarly, the number of liver-
related deaths would decrease by 80% from the base, with
30 deaths in 2030. Decompensated and compensated cir-
rhosis would decrease by 85% and 90%, respectively, from
the base, with 50 and 470 cases in 2030.
Pakistan
Increased efficacy only
There would be 360 000 fewer viremic individuals in
2030, a 5% reduction compared to the base case. The
number of HCC cases in 2030 was estimated at 30 200
cases, an 8% decrease from the base case. Similarly, the
number of liver-related deaths would decrease by 8% from
the base, with 28 200 deaths in 2030. Decompensated
and compensated cirrhosis would decrease by 8–9% from
the base, with 89 000 and 610 000 cases, respectively, in
2030.
Increased efficacy & treatment uptake
Utilizing an aggressive treatment strategy, there would be
a 90% reduction in the total number of viremic individu-
als, representing 6 754 000 fewer viremic individuals, in
2030, relative to the base case. The number of HCC cases
in 2030 was estimated at 5100 cases, an 85% decrease
from the base case. Similarly, the number of liver-related
deaths would decrease by 80% from the base, with 5900
deaths in 2030. Decompensated and compensated cirrhosis
would decrease by 85% from the base, with 13 500 and
102 000 cases in 2030.
Romania
Increased efficacy only
There would be 17 400 fewer viremic individuals in 2030,
a 4% reduction as compared to the base case. The number
of HCC cases in 2030 was estimated at 2200 cases, a 9%
reduction from the base case. Similarly, the number of
© 2015 John Wiley & Sons Ltd
58 F. Z. Alfaleh et al.
liver-related deaths would decrease by 10% from the base
scenario, with 3100 deaths in 2030. Decompensated and
compensated cirrhosis would decrease by 12% and 7%,
respectively, from the base, with 7200 and 72 600 cases
in 2030.
Increased efficacy & treatment uptake
With an increased treatment and diagnosis strategy, there
would be 76 000 fewer viremic individuals in 2030, a
17% reduction as compared to the base case. The number
of HCC cases in 2030 was estimated at 1200 cases, a 45%
decrease from the base case. Similarly, the number of liver-
related deaths would decrease by 50% from the base, with
1700 deaths in 2030. Decompensated and compensated
cirrhosis would decrease by 55% and 40%, respectively,
from the base, with 3700 and 45 900 cases in 2030.
Saudi Arabia
Increased efficacy only
Increasing the efficacy of treatment would result in
22 100 fewer viremic cases in 2030, a 21% reduction
from the base scenario. The number of HCC cases would
decrease by 27% to 350 cases in 2030. Liver-related mor-
tality would be reduced to 480 deaths in 2030, a 28%
decrease. Decompensated and compensated cirrhosis would
decrease by 34% and 26%, respectively, compared with
the base scenario, to 850 and 11 500 cases in 2030.
Increased efficacy & treatment uptake
With an aggressive treatment strategy, viremic prevalence
would be reduced to 1700 cases in 2030, an almost 100%
decrease compared with the base scenario. Cases of HCC
would be 100% fewer at 1 case by 2030. Liver-related
mortality would drop by 95% compared with the base
scenario to 20 deaths in 2030. Cases of decompensated
and compensated cirrhosis would be 6 and 130 in 2030,
respectively; nearly 100% reduced compared with the base
scenario.
Slovenia
Increased efficacy only
There would be 210 fewer viremic individuals in 2030, a
4% reduction as compared to the base case. The number
of HCC cases in 2030 was estimated at 20 cases, a 5%
decrease from the base case. Similarly, the number of liver-
related deaths would decrease by 5% from the base, with
25 deaths in 2030. Decompensated and compensated cir-
rhosis would decrease by 6% and 5% from the base, with
60 and 640 cases, respectively, in 2030.
Increased efficacy & treatment uptake
By scaling up the number of newly diagnosed and treated
patients and starting higher efficacy treatments in 2016,
there would be an estimated 4600 fewer viremic individu-
als in 2030, a 90% reduction from the base case. Liver-re-
lated deaths would decrease by 80% from the base, with 6
cases in 2030. Similarly, the number of HCC cases would
decrease by 85%, with 3 cases in 2030. Decompensated
and compensated cirrhosis would decrease by 85% and
90%, respectively, from the base, with 10 and 80 cases in
2030.
South Korea
Increased efficacy only
There would be 7700 fewer viremic individuals in 2030, a
5% reduction as compared to the base case. The number
of HCC cases in 2030 was estimated at 1400 cases, a 5%
decrease from the base case. Similarly, the number of liver-
related deaths would decrease by 4% from the base, with
1900 in 2030. Decompensated and compensated cirrhosis
would decrease by 4% and 5% from the base, with 3700
and 31 400 cases, respectively, in 2030.
Increased efficacy & treatment uptake
There would be 134 000 fewer viremic individuals in
2030, a 90% reduction as compared to the base case. The
number of HCC cases in 2030 was estimated at 240 cases,
an 85% decrease from the base case. Similarly, the number
of liver-related deaths would decrease by 75% from the
base, with 450 deaths in 2030. Decompensated and com-
pensated cirrhosis would decrease by 80% and 85%, respec-
tively, from the base, with 750 and 4900 cases in 2030.
UAE
Increased efficacy only
Increasing the efficacy of treatment to the post-2014 stan-
dard of care resulted in 720 fewer viremic cases in 2030,
a 9% change from the base scenario. The number of HCC
cases decreased by 10% to 40 cases in 2030. Liver-related
mortality was reduced to 60 deaths in 2030, a 10%
decrease. Decompensated and compensated cirrhosis
decreased by 15% and 10%, respectively, compared with
the base scenario, to 90 and 1300 cases in 2030.
Increased efficacy & treatment uptake
With an aggressive treatment strategy, viremic prevalence
was reduced to 240 cases in 2030, a 95% decrease com-
pared with the base scenario. Cases of HCC and liver-re-
lated mortality were eliminated by 2030. Cases of
decompensated and compensated cirrhosis were <5 each in
2030, >99% decreases compared with the base scenario.
DISCUSSION
This analysis suggests that successful diagnosis and treat-
ment of a small proportion of patients can contribute
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significantly to the reduction in disease burden in the
countries studied. As could be expected, the largest reduc-
tion in HCV-related morbidity and mortality occurs when
increased treatment is combined with higher efficacy thera-
pies, generally in combination with increased diagnosis.
However, for most countries presented in this analysis, this
will require a 3–5 fold increase in diagnosis and/or treat-
ment. Thus, building the public health and clinical provi-
der capacity for improved diagnosis and treatment will be
critical.
Using today’s treatment paradigm, HCV-related morbid-
ity and mortality is expected to increase past 2030 in most
countries, with the exception of Japan and South Korea
[1]. Additionally, in nine countries, the total number of
HCV-infected individuals is expected to increase or remain
flat – Hungary, Iceland, Indonesia, Iran, Latvia, Lebanon,
Lithuania, Pakistan and Saudi Arabia.
This analysis demonstrates that with a treatment rate of
approximately 10%, it is possible to achieve elimination of
HCV (>90% drop in total infections by 2030). In addition,
it highlights that switching to high SVR therapies would
reduce HCV-related morbidity and mortality in many coun-
tries. This impact is magnified in countries which already
have higher treatment rates of >2.0% – Estonia, Hungary,
Iceland, Iran, Japan, Latvia, Lebanon and Slovenia.
As part of this analysis, two broad categories of strate-
gies were generally investigated: disease control and HCV
elimination. In the former case, the future SVR, as well as
eligible, treated and diagnosed populations, was modified
to keep HCV morbidity and mortality at the same level as
2014. In the latter case, the same variables were modified
to get the total number of infections below 10% of 2014
values. In a few countries, achieving a specific goal was of
greater interest, or was deemed to be more realistic than
an elimination or mortality prevention strategy, given the
current situation in the country. For example, in Romania,
an 18% reduction in viremic cases was deemed an achiev-
able goal.
A key observation of this analysis was that increased
treatment and SVR in patients who were >F2 had the lar-
gest impact in reducing morbidity and mortality. However,
treatment of F0–F1 patients was necessary if the goal of
the strategy was to eliminate HCV. In fact, the most effec-
tive strategy identified was to increase treatment in >F2
patients until that patient pool was depleted, and then to
expand treatment to all. However, this strategy did have a
major drawback. The HCV infected population is ageing,
and waiting to treat early-stage patients meant that some
would be too old to be treated. The age of the infected
population is one of the key variables for not being able to
feasibly achieve zero infections in a country. Another fac-
tor that would likely prevent reaching complete eradication
is immigration in today’s mobile society. The models sug-
gested that some new cases always entered the country
through immigration. The long-term goal of HCV eradica-
tion will require a global effort to eliminate the virus across
borders.
Estonia
Under the current treatment structure, the prevalence of
chronic HCV was projected to decrease by 30%, which is
substantial compared with some of the other countries pre-
sented here. A moderate treatment rate (2.6%) and infec-
tion rate (15.6 per 100 000) are likely contributors to the
projected decline. In this analysis, it was found that the
adoption of higher SVR therapies among patients with
advanced fibrosis (≥F3) would have a substantial impact on
the burden of advanced disease (60–75%), even without
increasing treatment rates. Combined with an increased
treatment rate up to 4.8%, there was an additional benefit
of a 50% reduction in total viremic infections.
Treatment in Estonia is provided at two large regional
hospitals as well as four city hospitals; however, treatment
must be prescribed by an infectious disease specialist or a
gastroenterologist. Long wait lists for consultations with
these specialists may provide a barrier to increasing the
number of patients treated in the future.
Hungary
Under the current treatment structure, the prevalence of
chronic HCV was projected to decrease by 3%. However,
cases of advanced liver disease and liver-related deaths are
projected to continue to rise (50–60%). In this analysis, it
was found that the adoption of higher SVR therapies
would have a moderate impact on the burden of advanced
disease (20–25%), even without increasing treatment rates.
Under the second scenario, average SVR was increased
from 55% in 2014 to 90% in 2015 (among those with a
fibrosis score ≥F0 or ≥F1). Treatment was expanded to a
fibrosis score ≥F0 for all genotypes in 2019. The number
of treated patients was increased from 1200 in 2014 to
8850 by 2021, while the number of newly diagnosed cases
had to be increased from 2090 in 2014 to 6880 cases by
2021 to provide a sufficient pool of diagnosed patients to
treat. A combination of increased treatment, SVR and diag-
nosis would have a substantial impact on the burden of
advanced disease (90–100%). The projected impact of
these scenarios will facilitate disease forecasting, resource
planning and rational strategies for HCV management in
Hungary.
Iceland
There are few studies exploring the prevalence of HCV
among the Icelandic population, but data suggest that
HCV infection rates are relatively low. However, chronic
HCV infection is a major contributor towards advanced
liver disease in Iceland; a study of 99 cirrhotic patients
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found that 24% were HCV positive [8]. With current
treatment levels, prevalence is projected to increase
through 2030. A scenario focused on increased treatment
efficacy alone had relatively little impact on overall dis-
ease burden. To reduce HCV-related morbidity and mor-
tality, increases in the annual number of treated patients
are necessary. By increasing treatment to a maximum of
160 cases annually, viremic prevalence decreased to
<0.1% by 2030.
Indonesia
Under the current treatment structure, the number of indi-
viduals infected with chronic HCV was projected to remain
relatively stable through 2030. Currently, only 230
patients (<0.01%) are estimated to be treated annually in
Indonesia. Although some patients travel abroad to receive
treatment and liver transplantation, they have not been
considered here. Increasing SVR in the absence of an
increased number of treated patients would have a negligi-
ble impact on viremic cases or advanced disease progres-
sion. Increasing the treatment rate to 3.8% by 2020
would have a large impact on the number of viremic indi-
viduals by 2030 (45% reduction), with an even greater
impact on the number of liver-related deaths (60% reduc-
tion) as compared with the base case. To achieve such
reductions, a substantial increase in the annual number of
diagnosed patients would be necessary (145 680 new
cases diagnosed annually by 2019).
Within the last year, the Indonesian Ministry of Health
has developed a road map to address the increasing burden
of HCV. One primary goal of this plan is to improve the
lives of 30% of patients by 2019, through services includ-
ing diagnosis and treatment. It is estimated that at most
10% of the HCV-infected Indonesian population is aware of
their infection, so strategies involving an increase in the
number of treated patients would likely require increased
screening and diagnosis.
Iran
Iran has one of the lowest rates of HCV prevalence in the
Middle East. Under the current treatment paradigm, HCV
infections will increase in Iran. Much more problematic
are the expected large increases in the disease burden that
will occur due to the ageing of the currently young
infected population. This provides Iran with a unique
opportunity to halt the growing disease burden before it
becomes overwhelming. Complementary to this is the fact
that young infected individuals have both higher eligibility
as well as SVR rates.
While increasing efficacy has moderate declines in all
HCV-related indicators, an aggressive treatment strategy
would eliminate HCV in Iran, bringing the viremic preva-
lence to approximately 0.02% by 2030. This can be
achieved through a national strategy that would increase
treatment by 5000 individuals every year starting in 2016
until reaching a maximum treatment of 20 500 in 2018.
By treating over 20 000 individuals annually for 5 years,
the treatment could then decrease to below current levels
by 2030. Due to the large numbers of individuals being
treated, there would need to be an increase in diagnosis
rate to keep pace with the treatment rate. Utilizing a birth
cohort with the young infected population could make
diagnosis, treatment and thus elimination, a real possibility
in Iran.
Japan
Given high HCV prevalence among the older adults in
Japan [9], the HCV-infected population is rapidly ageing,
and the infected population will decline in future years.
The occurrence of substantial numbers of incident HCV-at-
tributable HCC cases began decades earlier in Japan as
compared with the USA [10], and the burden of HCV-at-
tributable advanced liver disease is now declining in Japan.
However, the burden of disease is still notable, with over
half of HCC cases in Japan occurring among HCV-infected
individuals [11]. A scenario focused on increased treatment
efficacy alone had a relatively large impact on HCC inci-
dence by 2030. By increasing the annual treated popula-
tion by a relatively small number, a 75% reduction in HCC
incidence would be possible by 2030.
Latvia
Under the current treatment structure, the prevalence of
chronic HCV is projected to increase through 2030.
Despite a treatment rate of approximately 2.0%, the rate of
new infections (97 per 100 k) due to continued transmis-
sion through injection drug use (IDU) and in the general
community and medical settings may hinder efforts to miti-
gate the burden of HCV in Latvia. In this analysis, it was
found that the adoption of higher SVR therapies would
have a small impact on the burden of advanced disease
(15%) and overall viremic cases (10%). Combined with an
increase in treatment rate (up to 2.7%), the burden of
advanced disease was reduced by 40–45% and overall vire-
mic infections by 25%.
Lebanon
Under the current treatment paradigm, the prevalence of
chronic HCV is projected to fall slightly by 2030, with a
4% decrease, but cases of advanced stage liver disease are
projected to increase by 18–30%. Adoption of higher effi-
cacy treatments alone would lead to a reduction in cases
of advanced stage liver disease, but would not result in
large differences in viremic prevalence from the current
treatment paradigm. Eradication could be possible with
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increased efficacy and treatment; however, awareness cam-
paigns and a national screening programme are needed to
increase diagnosis before major increases in treatment
rates can occur.
Lithuania
Under the current treatment structure, the prevalence of
chronic HCV was projected to remain relatively flat, with a
5% increase by 2030. A modest treatment rate (1.4%) and
high incidence rate (35 cases per 100 000 persons) may
contribute to this sustained prevalence. In this analysis, it
was found that the adoption of higher SVR therapies, in
the absence of an increased number of patients treated,
would have a minimal impact on viremic cases and
advanced disease (8–9% reduction). Increasing the treat-
ment rate to 14.9% by 2020 would have a substantial
impact on the number of viremic individuals and advanced
outcomes by 2030 (80–90% reduction) as compared with
the base case.
Pakistan
Although Pakistan has one of the largest numbers of
infected individuals in the world, with an estimated
231 100 new cases each year, the total number of infected
is increasing under the current treatment paradigm. The
HCV-infected population in Pakistan is older, with greater
occurrence of advanced disease sequelae and a relatively
low treatment rate. These factors contribute to the fact
that increasing SVR will have a minimal effect, a 5%
decrease from the base case, on the infected population.
To truly mitigate the HCV disease burden in Pakistan,
one needs to address the trinity of prevention, treatment
and diagnosis. A major step in prevention would be a
nationwide transition to the use of syringes with reuse
prevention features, as nosocomial transmission is the
major mode of transmission in Pakistan. With such a large
infected population, it is imperative to increase treatment.
By increasing treatment to 510 000 individuals for
13 years, there would be an estimated 90% reduction in
the total number of viremic individuals. The increase in
diagnosis is only required to keep pace with the increase in
the number of individuals treated. By addressing these
three areas, Pakistan provides evidence that even in a
highly endemic and low income country, HCV can be elim-
inated via a cohesive national strategy.
Romania
The number of viremic infections is expected to decrease
25% by 2030, despite low treatment rates and efficacy
under the current treatment paradigm, due to an ageing
infected population. HCV prevalence in individuals aged
60–69 years is almost double that of individuals aged
50–59 years [12]. Large increases in the annual diag-
nosed and treated population are necessary to reduce the
number of viremic individuals in Romania, but increasing
treatment efficacy and gradually increasing treatment
rates to three times the current rate would reduce rates
of HCC and decompensated cirrhosis by 50–55% by
2030. Modelling an increased efficacy and treatment sce-
nario required an increase in diagnosis by 10–25% each
year that treatment was increased. Under the base case,
<20% of the prevalent population was living with a diag-
nosis in 2014.
Saudi Arabia
Under the current treatment strategy, the number of vire-
mic cases of HCV is expected to remain stable through
2030. While the incidence rate is moderate (11 cases per
100 000 persons), this is likely only partially offset by a
low treatment rate (2%). However, modelling the use of
advanced SVR therapies showed a 50–70% reduction in
advanced stage HCV and liver-related mortality. Modelling
increased SVR therapies and an increase in treatment from
380 to 5180 patients in 2017 and 9780 patients in 2020
would result in an almost 100% reduction in prevalence
and >95% reduction in advanced stage HCV. Such a sce-
nario requires that the number of patients diagnosed
increases significantly along with the number treated. A
national strategy to achieve these outcomes would likely
require an aggressive screening programme.
Slovenia
In Slovenia, the national strategy for the control of HCV
infection was set up in 1997, together with the National
Viral Hepatitis Expert Group, for the management of HCV
regarding diagnosing, treatment and prevention. Incidence
of HCV in Slovenia is declining due to awareness
campaigns, introduction of free-of-charge anonymous HCV
testing and routine testing and counselling in the national
healthcare network of 18 centres for the prevention and
treatment of drug addiction that are integrated to five spe-
cialized clinics for HCV treatment [13]. Treated patients
under the current treatment paradigm have, on average,
an 80% SVR due to treatment optimization efforts, rigorous
follow-up and adherence to treatment. As a result, viremic
prevalence is projected to decrease by 20% by 2030. For
this reason, increasing SVR only has little effect on the
projected number of viremic cases compared with some of
the other countries presented here, which often have lower
base efficacy rates. In Slovenia, viremic patients are treated
without restrictions, yet the detection rate, including in
those with advanced liver disease, is relatively low. An
increase in detection of HCV-infected patients with
advanced liver disease and, if necessary, restricting avail-
able treatment regimens to more advanced cases would
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cause a greater reduction in HCC, compensated cirrhosis
and decompensated cirrhosis.
By incrementally increasing the number of annually
treated patients to 590 in 2026 from a base of 150, Slove-
nia could achieve a 90% reduction in prevalence by 2030.
Increasing treatment rates starting in 2016 would require
the annual diagnosis rate to increase to 350 patients by
2019. Approximately half of the viremic cases in Slovenia
have already been diagnosed.
South Korea
The burden of HCV in South Korea is largely concen-
trated in the older adult population, with relatively few
new infections occurring annually (7.8 cases per
100 000 persons). As the population ages, the number of
advanced stage patients will peak around 2020, before
decreasing to 10–20% below 2014 values in 2030. Cur-
rently, 1.9% of viremic patients are treated annually,
with an average SVR of 74%. Increasing SVR in the
absence of an increased number of treated patients would
have a minimal impact on viremic cases and advanced
disease progression by 2030 (5% reduction). A 90%
reduction in viremic cases would require an incremental
increase in the number of treated patients, from 4500
annually in 2014 to 16 300 annually in 2020, with a
simultaneous increase in the number of diagnosed cases
(from 8050 annually in 2014 to 12 800 annually in
2030). Additionally, due to the ageing older population,
treatment of adults up to 74 years of age would be neces-
sary beginning in 2017 with treatment of adults up to
84 years of age by 2025.
UAE
Under the pre-DAA treatment strategy, the number of
viremic cases of HCV would be expected to decrease stea-
dily by 26% from 2014 to 2030. While the incidence
rate is low (7.5 cases per 100 000 persons), this is likely
only partially offset by a low treatment rate (1.3%). How-
ever, modelling the use of advanced SVR therapies, which
were indeed introduced to the UAE in 2014, showed a
10–15% reduction in advanced stage HCV and liver-re-
lated mortality. Modelling increased SVR therapies and an
increase in treatment from 140 to 950 patients per year
in years 2015–2025 would result in a 95% decrease in
prevalence and >99% reduction in advanced stage HCV.
Such a scenario requires that the number of patients
diagnosed increases significantly along with the number
treated. A national strategy in this scenario would likely
require an aggressive screening programme. Although the
implementation of more effective therapies in the UAE
will help to reduce the burden of HCV, a scenario in
which treatment was expanded would have a significantly
greater impact.
Utility of HCV Screening
As shown previously [1,7], diagnosis remains low in
many countries. In some countries, the diagnosis rate
was modelled to increase to provide a sufficient patient
pool to achieve the desired strategy. However, it is not
clear whether the number of newly diagnosed patients
can realistically be increased without a focused screening
strategy.
In the United States, the Centers for Disease Control and
Prevention have recommended screening the birth cohorts
with a higher prevalence rate to allow for a more efficient
use of resources [14–16]. A birth cohort analysis was con-
ducted for the studied countries, and the results are shown
in Fig. 17. The analysis showed that there is, in fact, a
birth cohort effect for HCV in all countries, with over 70%
of the infected population falling within a specific range.
The range, in the countries analysed, was from 20 to
40 years, likely due to variations in risk factors. The range
was wider when nosocomial infection was identified as a
risk factor (e.g., blood transfusions prior to blood screen-
ing). In countries where IDU was identified as a key risk
factor, the birth cohort range often included individuals
born between 1980 and 1990. The birth year cohorts pro-
vide an efficient source for identifying new patients as part
of a national screening strategy.
There were a number of limitations with this study. SVR
rates for current treatment protocols were based on clinical
data from centres experienced in treating patients and
managing adverse events. SVR rates observed in other
treatment venues could be substantially lower [17] than
what is stated here, resulting in a larger difference between
the base case and each of the scenarios. In addition, there
is variance in HCV prevalence estimates [7]. Therefore, the
relative impact of each scenario may be more or less pro-
nounced if true prevalence is higher or lower than the esti-
mated values used in this analysis.
Another limitation was that modelled increases in treat-
ment rate, diagnosis rate, eligibility and SVR were assumed
to take effect immediately. In reality, the successful adop-
tion of new therapies and implementation of infection con-
trol strategies at the national level would take several
years to accomplish. However, analyses examining the
impact of accelerating or delaying increases in SVR or
treatment consistently demonstrated that desired outcomes
were more likely to be achieved when the strategies were
implemented earlier.
A final limitation of this analysis is that disease progres-
sion was considered to halt once patients were cured.
However, it has been shown that the risks of advanced
liver disease and related mortality can remain among
cured patients, but at markedly lower rates [18]. Therefore,
the model could overestimate the impact of curing patients
on overall HCV liver-related morbidity and mortality. Any
underestimation is likely to be minimal, as most reduction
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in HCV morbidity and mortality came from prevention of
HCV progression in earlier disease stages where progres-
sion to more advanced liver disease is unlikely.
This analysis demonstrated that the total number of
HCV infections is expected to decline or remain flat in most
countries. However, HCV-related morbidity and mortality
are expected to increase in almost all countries. Reducing
HCV disease burden is possible with a two-pronged effort,
where active screening programmes find and identify HCV-
infected individuals and where active management with
antiviral therapy is maintained.
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